DOCSLIB.ORG

Mouse Gnai3 Knockout Project (CRISPR/Cas9)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

https://www.alphaknockout.com Mouse Gnai3 Knockout Project (CRISPR/Cas9) Objective: To create a Gnai3 knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Gnai3 gene (NCBI Reference Sequence: NM_010306 ; Ensembl: ENSMUSG00000000001 ) is located on Mouse chromosome 3. 9 exons are identified, with the ATG start codon in exon 1 and the TGA stop codon in exon 8 (Transcript: ENSMUST00000000001). Exon 2~5 will be selected as target site. Cas9 and gRNA will be co-injected into fertilized eggs for KO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Mice homozygous for a knock-out allele exhibit normal basal cardiac function and beta-adrenergic sensitivity. Mice homozygous for a different knock-out allele exhibit enhanced T cell migration toward CXCR3 agonists. Exon 2 starts from about 11.21% of the coding region. Exon 2~5 covers 44.44% of the coding region. The size of effective KO region: ~8075 bp. The KO region does not have any other known gene. Page 1 of 8 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele 5' gRNA region gRNA region 3' 1 2 3 4 5 9 Legends Exon of mouse Gnai3 Knockout region Page 2 of 8 https://www.alphaknockout.com Overview of the Dot Plot (up) Window size: 15 bp Forward Reverse Complement Sequence 12 Note: The 2000 bp section upstream of Exon 2 is aligned with itself to determine if there are tandem repeats. No significant tandem repeat is found in the dot plot matrix. So this region is suitable for PCR screening or sequencing analysis. Overview of the Dot Plot (down) Window size: 15 bp Forward Reverse Complement Sequence 12 Note: The 2000 bp section downstream of Exon 5 is aligned with itself to determine if there are tandem repeats. Tandem repeats are found in the dot plot matrix. The gRNA site is selected outside of these tandem repeats. Page 3 of 8 https://www.alphaknockout.com Overview of the GC Content Distribution (up) Window size: 300 bp Sequence 12 Summary: Full Length(2000bp) | A(30.4% 608) | C(16.65% 333) | T(29.1% 582) | G(23.85% 477) Note: The 2000 bp section upstream of Exon 2 is analyzed to determine the GC content. No significant high GC-content region is found. So this region is suitable for PCR screening or sequencing analysis. Overview of the GC Content Distribution (down) Window size: 300 bp Sequence 12 Summary: Full Length(2000bp) | A(28.9% 578) | C(18.95% 379) | T(30.6% 612) | G(21.55% 431) Note: The 2000 bp section downstream of Exon 5 is analyzed to determine the GC content. No significant high GC-content region is found. So this region is suitable for PCR screening or sequencing analysis. Page 4 of 8 https://www.alphaknockout.com BLAT Search Results (up) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 2000 1 2000 2000 100.0% chr3 - 108123838 108125837 2000 browser details YourSeq 116 480 939 2000 88.7% chr7 + 27237015 27313755 76741 browser details YourSeq 110 446 604 2000 89.9% chr13 - 95555319 95555662 344 browser details YourSeq 106 446 611 2000 92.2% chr3 + 33757578 33757746 169 browser details YourSeq 105 455 888 2000 87.8% chr13 + 100753546 101069343 315798 browser details YourSeq 104 449 644 2000 92.7% chr9 + 119900678 119901215 538 browser details YourSeq 103 449 612 2000 93.4% chr2 + 151792095 151792486 392 browser details YourSeq 102 446 614 2000 91.2% chr7 + 82654515 82654686 172 browser details YourSeq 99 482 609 2000 89.1% chrX - 134610714 134610842 129 browser details YourSeq 98 446 609 2000 91.0% chr2 - 101669440 101669606 167 browser details YourSeq 95 447 609 2000 92.2% chr7 + 139203106 139203274 169 browser details YourSeq 93 441 561 2000 91.9% chr10 - 40585933 40586056 124 browser details YourSeq 93 482 607 2000 91.9% chr19 + 5173696 5173821 126 browser details YourSeq 92 474 611 2000 83.4% chr4 - 3981260 3981397 138 browser details YourSeq 92 441 561 2000 89.1% chr1 + 131949517 131949635 119 browser details YourSeq 90 446 611 2000 92.5% chr16 + 30031190 30031357 168 browser details YourSeq 90 446 561 2000 92.5% chr11 + 94324384 94324503 120 browser details YourSeq 89 480 608 2000 85.3% chr2 + 37448034 37448165 132 browser details YourSeq 89 480 611 2000 84.1% chr17 + 45529071 45529203 133 browser details YourSeq 88 446 561 2000 91.6% chr11 - 79721251 79721370 120 Note: The 2000 bp section upstream of Exon 2 is BLAT searched against the genome. No significant similarity is found. BLAT Search Results (down) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN -------------------------------------------------------------------------------------------------------------- browser details YourSeq 2000 1 2000 2000 100.0% chr3 - 108113763 108115762 2000 browser details YourSeq 286 973 1438 2000 97.4% chr4 - 40838584 41139766 301183 browser details YourSeq 266 964 1435 2000 96.6% chr8 + 88112875 88177817 64943 browser details YourSeq 255 973 1441 2000 94.5% chr11 + 102243739 102244226 488 browser details YourSeq 250 964 1441 2000 94.6% chrX - 20460655 20461270 616 browser details YourSeq 247 976 1441 2000 95.3% chr3 - 34712155 34758708 46554 browser details YourSeq 245 974 1441 2000 88.0% chr4 - 148541182 148541521 340 browser details YourSeq 219 997 1439 2000 87.7% chr1 + 157142376 157142645 270 browser details YourSeq 209 973 1385 2000 88.7% chr16 - 16942243 16942483 241 browser details YourSeq 204 1016 1441 2000 89.3% chr18 - 36393772 36394101 330 browser details YourSeq 193 1044 1441 2000 86.6% chr10 + 81159433 81159685 253 browser details YourSeq 179 1028 1441 2000 89.9% chr16 - 44279164 44279543 380 browser details YourSeq 175 983 1441 2000 84.9% chr12 - 111661514 111661767 254 browser details YourSeq 172 974 1434 2000 87.8% chr2 + 153533090 153533390 301 browser details YourSeq 172 981 1434 2000 95.8% chr11 + 4706401 4706880 480 browser details YourSeq 169 1271 1441 2000 99.5% chr10 + 85931875 85932045 171 browser details YourSeq 168 1027 1434 2000 88.7% chr1 + 152078687 152078913 227 browser details YourSeq 166 1268 1440 2000 98.3% chr1 - 68893582 68893755 174 browser details YourSeq 166 1016 1434 2000 87.7% chr6 + 34911978 34912181 204 browser details YourSeq 164 1274 1441 2000 98.9% chr4 - 143196612 143196779 168 Note: The 2000 bp section downstream of Exon 5 is BLAT searched against the genome. No significant similarity is found. Page 5 of 8 https://www.alphaknockout.com Gene and protein information: Gnai3 guanine nucleotide binding protein (G protein), alpha inhibiting 3 [ Mus musculus (house mouse) ] Gene ID: 14679, updated on 15-Oct-2019 Gene summary Official Symbol Gnai3 provided by MGI Official Full Name guanine nucleotide binding protein (G protein), alpha inhibiting 3 provided by MGI Primary source MGI:MGI:95773 See related Ensembl:ENSMUSG00000000001 Gene type protein coding RefSeq status VALIDATED Organism Mus musculus Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus Also known as Gnai-3; AI158965; AW537698; Galphai3 Expression Ubiquitous expression in placenta adult (RPKM 67.1), CNS E11.5 (RPKM 42.8) and 26 other tissues See more Orthologs human all Genomic context Location: 3 F2.3; 3 46.83 cM See Gnai3 in Genome Data Viewer Exon count: 9 Annotation release Status Assembly Chr Location 108 current GRCm38.p6 (GCF_000001635.26) 3 NC_000069.6 (108107275..108146152, complement) Build 37.2 previous assembly MGSCv37 (GCF_000001635.18) 3 NC_000069.5 (107910217..107949032, complement) Chromosome 3 - NC_000069.6 Page 6 of 8 https://www.alphaknockout.com Transcript information: This gene has 1 transcript Gene: Gnai3 ENSMUSG00000000001 Description guanine nucleotide binding protein (G protein), alpha inhibiting 3 [Source:MGI Symbol;Acc:MGI:95773] Gene Synonyms Galphai3 Location Chromosome 3: 108,107,280-108,146,146 reverse strand. GRCm38:CM000996.2 About this gene This gene has 1 transcript (splice variant), 216 orthologues, 15 paralogues, is a member of 1 Ensembl protein family and is associated with 6 phenotypes. Transcripts Name Transcript ID bp Protein Translation ID Biotype CCDS UniProt Flags Gnai3-201 ENSMUST00000000001.4 3262 354aa ENSMUSP00000000001.4 Protein coding CCDS17751 Q9DC51 TSL:1 GENCODE basic APPRIS P1 58.87 kb Forward strand 108.10Mb 108.11Mb 108.12Mb 108.13Mb 108.14Mb 108.15Mb Genes Gnat2-201 >protein coding (Comprehensive set... Gnat2-206 >protein coding Gnat2-204 >retained intron Gnat2-203 >protein coding Gnat2-202 >lncRNA Contigs AL671854.14 > Genes (Comprehensive set... < Gnai3-201protein coding < Gpr61-201protein coding < Gpr61-202nonsense mediated decay Regulatory Build 108.10Mb 108.11Mb 108.12Mb 108.13Mb 108.14Mb 108.15Mb Reverse strand 58.87 kb Regulation Legend CTCF Enhancer Open Chromatin Promoter Promoter Flank Gene Legend Protein Coding Ensembl protein coding merged Ensembl/Havana Non-Protein Coding processed transcript RNA gene Page 7 of 8 https://www.alphaknockout.com Transcript: ENSMUST00000000001 < Gnai3-201protein coding Reverse strand 38.87 kb ENSMUSP00000000... Low complexity (Seg) Superfamily G protein alpha subunit, helical insertion P-loop containing nucleoside triphosphate hydrolase SMART Guanine nucleotide binding protein (G-protein), alpha subunit Prints G-protein alpha subunit, group I Guanine nucleotide binding protein (G-protein), alpha subunit Pfam Guanine nucleotide binding protein (G-protein), alpha subunit PANTHER PTHR10218:SF230 Guanine nucleotide binding protein (G-protein), alpha subunit Gene3D 3.40.50.300 G protein alpha subunit, helical insertion CDD Guanine nucleotide binding protein (G-protein), alpha subunit All sequence SNPs/i... Sequence variants (dbSNP and all other sources) Variant Legend missense variant synonymous variant Scale bar 0 40 80 120 160 200 240 280 354 We wish to acknowledge the following valuable scientific information resources: Ensembl, MGI, NCBI, UCSC. Page 8 of 8.
Recommended publications
  • G Protein Alpha Inhibitor 1 (GNAI1) Rabbit Polyclonal Antibody Product Data

    G Protein Alpha Inhibitor 1 (GNAI1) Rabbit Polyclonal Antibody Product Data

    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TA335036 G protein alpha inhibitor 1 (GNAI1) Rabbit Polyclonal Antibody Product data: Product Type: Primary Antibodies Applications: WB Recommended Dilution: WB Reactivity: Human, Mouse, Rat Host: Rabbit Isotype: IgG Clonality: Polyclonal Immunogen: The immunogen for anti-GNAI1 antibody: synthetic peptide directed towards the middle region of human GNAI1. Synthetic peptide located within the following region: YQLNDSAAYYLNDLDRIAQPNYIPTQQDVLRTRVKTTGIVETHFTFKDLH Formulation: Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. Note that this product is shipped as lyophilized powder to China customers. Purification: Affinity Purified Conjugation: Unconjugated Storage: Store at -20°C as received. Stability: Stable for 12 months from date of receipt. Predicted Protein Size: 40 kDa Gene Name: G protein subunit alpha i1 Database Link: NP_002060 Entrez Gene 14677 MouseEntrez Gene 25686 RatEntrez Gene 2770 Human P63096 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 4 G protein alpha inhibitor 1 (GNAI1) Rabbit Polyclonal Antibody – TA335036 Background: Guanine nucleotide-binding proteins (G proteins) form a large family of signal-transducing molecules. They are found as heterotrimers made up of alpha, beta, and gamma subunits. Members of the G protein family have been characterized most extensively on the basis of the alpha subunit, which binds guanine nucleotide, is capable of hydrolyzing GTP, and interacts with specific receptor and effector molecules.
  • Clinical and Genetic Investigation of a Large Tunisian Family with Complete Achromatopsia: Identification of a New Nonsense Mutation in GNAT2 Gene

    Clinical and Genetic Investigation of a Large Tunisian Family with Complete Achromatopsia: Identification of a New Nonsense Mutation in GNAT2 Gene

    Journal of Human Genetics (2011) 56, 22–28 & 2011 The Japan Society of Human Genetics All rights reserved 1434-5161/11 $32.00 www.nature.com/jhg ORIGINAL ARTICLE Clinical and genetic investigation of a large Tunisian family with complete achromatopsia: identification of a new nonsense mutation in GNAT2 gene Farah Ouechtati1,2,7, Ahlem Merdassi2,7, Yosra Bouyacoub1,2, Leila Largueche2, Kaouther Derouiche2, Houyem Ouragini1, Sonia Nouira1, Leila Tiab3,4, Karim Baklouti2, Ahmed Rebai5, Daniel F Schorderet3,4,6, Francis L Munier3,4,6, Leonidas Zografos4,6, Sonia Abdelhak1 and Leila El Matri2 Complete achromatopsia is a rare autosomal recessive disease associated with CNGA3, CNGB3, GNAT2 and PDE6C mutations. This retinal disorder is characterized by complete loss of color discrimination due to the absence or alteration of the cones function. The purpose of the present study was the clinical and the genetic characterization of achromatopsia in a large consanguineous Tunisian family. Ophthalmic evaluation included a full clinical examination, color vision testing and electroretinography. Linkage analysis using microsatellite markers flanking CNGA3, CNGB3, GNAT2 and PDE6C genes was performed. Mutations were screened by direct sequencing. A total of 12 individuals were diagnosed with congenital complete achromatopsia. They are members of six nuclear consanguineous families belonging to the same large consanguineous family. Linkage analysis revealed linkage to GNAT2. Mutational screening of GNAT2 revealed three intronic variations c.119À69G4C, c.161+66A4T and c.875À31G4C that co-segregated with a novel mutation p.R313X. An identical GNAT2 haplotype segregating with this mutation was identified, indicating a founder mutation. All patients were homozygous for the p.R313X mutation.
  • Supp Table 6.Pdf

    Supp Table 6.Pdf

    Supplementary Table 6. Processes associated to the 2037 SCL candidate target genes ID Symbol Entrez Gene Name Process NM_178114 AMIGO2 adhesion molecule with Ig-like domain 2 adhesion NM_033474 ARVCF armadillo repeat gene deletes in velocardiofacial syndrome adhesion NM_027060 BTBD9 BTB (POZ) domain containing 9 adhesion NM_001039149 CD226 CD226 molecule adhesion NM_010581 CD47 CD47 molecule adhesion NM_023370 CDH23 cadherin-like 23 adhesion NM_207298 CERCAM cerebral endothelial cell adhesion molecule adhesion NM_021719 CLDN15 claudin 15 adhesion NM_009902 CLDN3 claudin 3 adhesion NM_008779 CNTN3 contactin 3 (plasmacytoma associated) adhesion NM_015734 COL5A1 collagen, type V, alpha 1 adhesion NM_007803 CTTN cortactin adhesion NM_009142 CX3CL1 chemokine (C-X3-C motif) ligand 1 adhesion NM_031174 DSCAM Down syndrome cell adhesion molecule adhesion NM_145158 EMILIN2 elastin microfibril interfacer 2 adhesion NM_001081286 FAT1 FAT tumor suppressor homolog 1 (Drosophila) adhesion NM_001080814 FAT3 FAT tumor suppressor homolog 3 (Drosophila) adhesion NM_153795 FERMT3 fermitin family homolog 3 (Drosophila) adhesion NM_010494 ICAM2 intercellular adhesion molecule 2 adhesion NM_023892 ICAM4 (includes EG:3386) intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)adhesion NM_001001979 MEGF10 multiple EGF-like-domains 10 adhesion NM_172522 MEGF11 multiple EGF-like-domains 11 adhesion NM_010739 MUC13 mucin 13, cell surface associated adhesion NM_013610 NINJ1 ninjurin 1 adhesion NM_016718 NINJ2 ninjurin 2 adhesion NM_172932 NLGN3 neuroligin
  • The Specificity of Downstream Signaling for A1 and A2AR

    The Specificity of Downstream Signaling for A1 and A2AR

    biomedicines Article The Specificity of Downstream Signaling for A1 and A2AR Does Not Depend on the C-Terminus, Despite the Importance of This Domain in Downstream Signaling Strength Abhinav R. Jain 1 , Claire McGraw 1 and Anne S. Robinson 1,2,* 1 Department of Chemical and Biomolecular Engineering, Tulane University, New Orleans, LA 70118, USA; [email protected] (A.R.J.); [email protected] (C.M.) 2 Department of Chemical Engineering, Carnegie Mellon University, Pittsburgh, PA 15213, USA * Correspondence: [email protected]; Tel.: +1-412-268-7673 Received: 17 November 2020; Accepted: 9 December 2020; Published: 13 December 2020 Abstract: Recent efforts to determine the high-resolution crystal structures for the adenosine receptors (A1R and A2AR) have utilized modifications to the native receptors in order to facilitate receptor crystallization and structure determination. One common modification is a truncation of the unstructured C-terminus, which has been utilized for all the adenosine receptor crystal structures obtained to date. Ligand binding for this truncated receptor has been shown to be similar to full-length receptor for A2AR. However, the C-terminus has been identified as a location for protein-protein interactions that may be critical for the physiological function of these important drug targets. We show that variants with A2AR C-terminal truncations lacked cAMP-linked signaling compared to the full-length receptor constructs transfected into mammalian cells (HEK-293). In addition, we show that in a humanized yeast system, the absence of the full-length C-terminus affected downstream signaling using a yeast MAPK response-based fluorescence assay, though full-length receptors showed native-like G-protein coupling.
  • GNAI1 Antibody Cat

    GNAI1 Antibody Cat

    GNAI1 Antibody Cat. No.: 26-905 GNAI1 Antibody Antibody used in WB on Human brain at 0.2-1 ug/ml. Antibody used in WB on Hum. Fetal Brain at 1 ug/ml. Specifications HOST SPECIES: Rabbit SPECIES REACTIVITY: Drosophila, Human, Mouse, Rat Antibody produced in rabbits immunized with a synthetic peptide corresponding a region IMMUNOGEN: of human GNAI1. TESTED APPLICATIONS: ELISA, WB GNAI1 antibody can be used for detection of GNAI1 by ELISA at 1:12500. GNAI1 antibody APPLICATIONS: can be used for detection of GNAI1 by western blot at 1 μg/mL, and HRP conjugated secondary antibody should be diluted 1:50,000 - 100,000. POSITIVE CONTROL: 1) Cat. No. XBL-10123 - Fetal Brain Tissue Lysate PREDICTED MOLECULAR 40 kDa WEIGHT: September 27, 2021 1 https://www.prosci-inc.com/gnai1-antibody-26-905.html Properties PURIFICATION: Antibody is purified by peptide affinity chromatography method. CLONALITY: Polyclonal CONJUGATE: Unconjugated PHYSICAL STATE: Liquid Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% BUFFER: sucrose. CONCENTRATION: batch dependent For short periods of storage (days) store at 4˚C. For longer periods of storage, store STORAGE CONDITIONS: GNAI1 antibody at -20˚C. As with any antibody avoid repeat freeze-thaw cycles. Additional Info OFFICIAL SYMBOL: GNAI1 ALTERNATE NAMES: GNAI1, Gi ACCESSION NO.: NP_002060 PROTEIN GI NO.: 33946324 GENE ID: 2770 USER NOTE: Optimal dilutions for each application to be determined by the researcher. Background and References September 27, 2021 2 https://www.prosci-inc.com/gnai1-antibody-26-905.html Guanine nucleotide-binding proteins (G proteins) form a large family of signal-transducing molecules.
  • Supplementary Table S1. Summary of the Six Next-Generation Sequencing (NGS) Studies Containing 241 Paired Melanoma Tumor/Normal Samples

    Supplementary Table S1. Summary of the Six Next-Generation Sequencing (NGS) Studies Containing 241 Paired Melanoma Tumor/Normal Samples

    Supplementary Table S1. Summary of the six next-generation sequencing (NGS) studies containing 241 paired melanoma tumor/normal samples Study NGS # paired tumor-normal Tumor subtype Reference ID technology samples 1 Whole genome 25 23 cutaneous, 2 acral Berger et al., 2012 (1) 95 cutaneous, 5 acral, 2 mucosal, 1 uveal, and 18 2 Whole exome 121 Hodis et al., 2012 (2) unknown 61 cutaneous, 14 acral, 7 mucosal, 5 uveal, and 12 Krauthammer et al., 2012 3 Whole exome 99* unknown (3) 4 Whole exome 7 7 cutaneous Nikolaev et al., 2012 (4) 5 Whole exome 8 8 cutaneous Stark et al., 2012 (5) 6 Whole exome 14 14 cutaneous Wei et al., 2011 (6) 187 cutaneous, 19 acral, 9 mucosal, 6 uveal, and 30 Total 241# unknown *48 tumor samples without normal samples were excluded from our study. #23 paired samples in Berger et al. (2012) were used in Hodis et al. (2012). In addition, there were 10 samples without any mutations in Krauthammer et al. (2012). These samples were excluded in our analysis. 1 Supplementary Table S2. Summary of known driver mutations detected in the 241 melanoma samples Mutation* Type # samples BRAF GNAQ GNA11 KIT NRAS present Acral 17 3 1 0 0 0 2 Mucosal 7 2 1 0 0 0 1 Uveal 6 3 0 0 3 0 0 Cutaneous 182 138 99 0 0 1 38 Unknown 29 26 20 0 0 0 6 Total 172 121 241 0 (0%) 3 (1.2%) 1 (0.4%) 47 (19.5%) (frequency) (71.3%) (50.2%) *Includes the somatic point mutations identified by the Vanderbilt melanoma SNaPshot assay and known to be functional and actionable (7).
  • A Mixture of U.S. Food and Drug Administration–Approved Monoaminergic Drugs Protects the Retina from Light Damage in Diverse Models of Night Blindness

    A Mixture of U.S. Food and Drug Administration–Approved Monoaminergic Drugs Protects the Retina from Light Damage in Diverse Models of Night Blindness

    Physiology and Pharmacology A Mixture of U.S. Food and Drug Administration–Approved Monoaminergic Drugs Protects the Retina From Light Damage in Diverse Models of Night Blindness Henri Leinonen,1,2 Elliot H. Choi,1,2 Anthony Gardella,3 Vladimir J. Kefalov,4 and Krzysztof Palczewski1,2 1Gavin Herbert Eye Institute and the Department of Ophthalmology, University of California-Irvine, Irvine, California, United States 2Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio, United States 3Department of Ophthalmology and Visual Sciences, Case Western Reserve University, Cleveland, Ohio, United States 4Department of Ophthalmology and Visual Sciences, Washington University, St. Louis, Missouri, United States Correspondence: Krzysztof Palczewski, PURPOSE. The purpose of this study was to test the extent of light damage in different models Gavin Herbert Eye Institute, Depart- of night blindness and apply these paradigms in testing the therapeutic efficacy of ment of Ophthalmology, University of combination therapy by drugs acting on the Gi,Gs, and Gq protein-coupled receptors. California-Irvine, 850 Health Sciences Road, Irvine, CA 92697-4375, USA; METHODS. Acute bright light exposure was used to test susceptibility to light damage in mice [email protected]. lacking the following crucial phototransduction proteins: rod transducin (GNAT1), cone Submitted: January 3, 2019 transducin (GNAT2), visual arrestin 1 (ARR1), and rhodopsin kinase 1 (GRK1). Mice were Accepted: March 9, 2019 intraperitoneally injected with either vehicle or drug combination consisting of metoprolol (b1-receptor antagonist), bromocriptine (dopamine family-2 receptor agonist) and tamsulosin Citation: Leinonen H, Choi EH, Gar- (a -receptor antagonist) before bright light exposure. Light damage was primarily assessed della A, Kefalov VJ, Palczewski K.
  • Role for Protein Prenylation and "CAAX" Processing in Photoreceptor Neurons

    Role for Protein Prenylation and "CAAX" Processing in Photoreceptor Neurons

    Graduate Theses, Dissertations, and Problem Reports 2016 Role for protein prenylation and "CAAX" processing in photoreceptor neurons Nachiket D. Pendse Follow this and additional works at: https://researchrepository.wvu.edu/etd Recommended Citation Pendse, Nachiket D., "Role for protein prenylation and "CAAX" processing in photoreceptor neurons" (2016). Graduate Theses, Dissertations, and Problem Reports. 6397. https://researchrepository.wvu.edu/etd/6397 This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses, Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. For more information, please contact [email protected]. Role for protein prenylation and “CAAX” processing in photoreceptor neurons Nachiket D. Pendse Dissertation submitted to the Department of Biology at West Virginia University in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biology Visvanathan Ramamurthy, Ph.D., Chair Maxim Sokolov, Ph.D. Peter Mathers, Ph.D. Andrew Dacks, Ph.D. Shuo Wei, Ph.D. Graduate Program in Biology West Virginia University School of Medicine Morgantown, West Virginia 2016 Key Words: Prenylation, photoreceptor neurons, retina, phototransduction and vision Copyright 2016 Nachiket Pendse ABSTRACT Role for protein prenylation and “CAAX” processing in photoreceptor neurons Nachiket D.
  • GNAI1 Antibody (Monoclonal) (M01) Mouse Monoclonal Antibody Raised Against a Full Length Recombinant GNAI1

    GNAI1 Antibody (Monoclonal) (M01) Mouse Monoclonal Antibody Raised Against a Full Length Recombinant GNAI1

    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 GNAI1 Antibody (monoclonal) (M01) Mouse monoclonal antibody raised against a full length recombinant GNAI1. Catalog # AT2225a Specification GNAI1 Antibody (monoclonal) (M01) - Product Information Application WB, IHC, E Primary Accession P63096 Other Accession BC026326 Reactivity Human Host mouse Clonality Monoclonal Isotype IgG1 kappa Calculated MW 40361 GNAI1 Antibody (monoclonal) (M01) - Additional Information Antibody Reactive Against Recombinant Protein.Western Blot detection against Gene ID 2770 Immunogen (64.68 KDa) . Other Names Guanine nucleotide-binding protein G(i) subunit alpha-1, Adenylate cyclase-inhibiting G alpha protein, GNAI1 Target/Specificity GNAI1 (AAH26326, 1 a.a. ~ 354 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. Dilution WB~~1:500~1000 Format Clear, colorless solution in phosphate GNAI1 monoclonal antibody (M01), clone buffered saline, pH 7.2 . 2B8-2A5. Western Blot analysis of GNAI1 expression in human liver. Storage Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. Precautions GNAI1 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures. GNAI1 Antibody (monoclonal) (M01) - Protocols Page 1/3 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 Provided below are standard protocols that you may find useful for product applications. • Western Blot • Blocking Peptides • Dot Blot • Immunohistochemistry • Immunofluorescence • Immunoprecipitation • Flow Cytomety • Cell Culture Western Blot analysis of GNAI1 expression in transfected 293T cell line by GNAI1 monoclonal antibody (M01), clone 2B8-2A5.
  • Subunit Dissociation and Diffusion Determine the Subcellular Localization of Rod and Cone Transducins

    Subunit Dissociation and Diffusion Determine the Subcellular Localization of Rod and Cone Transducins

    5484 • The Journal of Neuroscience, May 16, 2007 • 27(20):5484–5494 Cellular/Molecular Subunit Dissociation and Diffusion Determine the Subcellular Localization of Rod and Cone Transducins Derek H. Rosenzweig,1* K. Saidas Nair,1* Junhua Wei,2 Qiang Wang,1 Greg Garwin,3 John C. Saari,3 Ching-Kang Chen,4 Alan V. Smrcka,5 Anand Swaroop,6 Janis Lem,7 James B. Hurley,2 and Vladlen Z. Slepak1 1Department of Molecular and Cellular Pharmacology and Neuroscience Program, University of Miami Miller School of Medicine, Miami, Florida 33136, Departments of 2Biochemistry and 3Ophthalmology, University of Washington, Seattle, Washington 98195, 4Department of Biochemistry, Virginia Commonwealth University, Richmond, Virginia 23284, 5Department of Pharmacology and Physiology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14603, 6Departments of Ophthalmology and Visual Sciences, and Human Genetics, University of Michigan, Ann Arbor, Michigan 48109, and 7Molecular Cardiology Research Institute, Tufts–New England Medical Center, Boston, Massachusetts 02111 Activation of rod photoreceptors by light induces a massive redistribution of the heterotrimeric G-protein transducin. In darkness, transducin is sequestered within the membrane-enriched outer segments of the rod cell. In light, it disperses throughout the entire neuron. We show here that redistribution of rod transducin by light requires activation, but it does not require ATP. This observation rules out participation of molecular motors in the redistribution process. In contrast to the light-stimulated redistribution of rod transducin in rods, cone transducin in cones does not redistribute during activation. Remarkably, when cone transducin is expressed in rods, it does undergo light-stimulated redistribution. We show here that the difference in subcellular localization of activated rod and coneG-proteinscorrelateswiththeiraffinityformembranes.Activatedrodtransducinreleasesfrommembranes,whereasactivatedcone transducin remains bound to membranes.
  • GNAI2 Monoclonal Antibody

    GNAI2 Monoclonal Antibody

    For Research Use Only GNAI2 Monoclonal antibody Catalog Number:67007-1-Ig 1 Publications www.ptgcn.com Catalog Number: GenBank Accession Number: CloneNo.: Basic Information 67007-1-Ig BC012138 3F6H5 Size: GeneID (NCBI): Recommended Dilutions: 1000 μg/ml 2771 WB 1:2000-1:6000 Source: Full Name: IF 1:50-1:500 Mouse guanine nucleotide binding protein (G Isotype: protein), alpha inhibiting activity IgG1 polypeptide 2 Purification Method: Calculated MW: Protein G purification 41 kDa Immunogen Catalog Number: Observed MW: AG28560 37 kDa Applications Tested Applications: Positive Controls: IF, WB,ELISA WB : HL-60 cells; U-937 cells, C6 cells, Raw 264.7 cells Cited Applications: IF : A431 cells; WB Species Specificity: Human, mouse, rat Cited Species: rabbit GNAI2, also named as GNAI2B, belongs to the G-alpha family. G(i/o/t/z) subfamily. Guanine nucleotide-binding Background Information proteins (G proteins) are involved as modulators or transducers in various transmembrane signaling systems. The G(i) proteins are involved in hormonal regulation of adenylate cyclase: they inhibit the cyclase in response to beta- adrenergic stimuli. GNAI2 is 93% homolog to GNAI1, 94% to GNAI3, 85% to GNAT3, 82% to GNAT2. Notable Publications Author Pubmed ID Journal Application Shuaishuai Hu 34440304 Genes (Basel) WB Storage: Storage Store at -20ºC. Stable for one year after shipment. Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3. Aliquoting is unnecessary for -20ºC storage For technical support and original validation data for this product please contact: This product is exclusively available under Proteintech T: 4006900926 E: [email protected] W: ptgcn.com Group brand and is not available to purchase from any other manufacturer.
  • Supplemental Materials and Methods Page

    Supplemental Materials and Methods Page

    1 2 Supplementary Information for 3 4 5 Vertebrate adaptive radiation is assembled from an ancient and disjunct spatiotemporal 6 landscape 7 8 Emilie J. Richards, Joseph A. McGirr, Jeremy R. Wang, Michelle E. St. John, Jelmer W. 9 Poelstra, Maria J. Solano, Delaney C. O’Connell, Bruce J. Turner, Christopher H. Martin* 10 11 *Correspondence to: [email protected] 12 13 14 15 This PDF file includes: 16 17 Supplementary text 18 Figures S1 to S17 19 Tables S1 to S19 20 SI References 21 22 Other supplementary materials for this manuscript include the following: 23 24 Datasets S1 to S9 25 26 27 28 29 30 31 32 33 34 35 36 37 1 38 Table of Contents 1. Supplemental Materials and Methods Page 1.1 Sampling 4 1.2 Genomic Library Prep 5 1.3 De novo genome assembly and annotation 5 1.4 Population genotyping. 6 1.5 Population genetic analyses 8 1.6 Mutation rate estimation. 10 1.7 Demographic Inferences 12 1.8 Introgression in SSI specialists 13 1.9 Search for candidate adaptive alleles in SSI specialists 15 1.10 Introgression in outgroup generalist populations 18 1.11. Characterization of adaptive alleles through GO analysis 19 1.12 Characterization of adaptive alleles through genome-wide association mapping 19 1.13 Characterization of adaptive alleles through differential gene expression and QTL 22 analysis from previous studies 1.14 Timing of divergence among adaptive alleles 23 1.15 Timing of selective sweeps on adaptive alleles 26 2. Supplementary Results and Discussion 31 2 2.1 Spatiotemporal stages of adaption based on timing of divergence among adaptive alleles 31 2.2 Spatiotemporal stages of adaptation based on timing of selection on adaptive alleles 35 3.